Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approves Quizartinib Plus Chemotherapy for Newly Diagnosed, FLT3-ITD+ AML

July 20th 2023

The FDA has approved quizartinib in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.

APVO436 Plus Venetoclax/Azacitidine Produces Durable Remissions in Relapsed/Refractory AML

July 20th 2023

Treatment with the CD3 x CD123 bispecific antibody APVO436 plus venetoclax and azacitidine led to durable remissions in patients with relapsed/refractory acute myeloid leukemia who had not received prior venetoclax.

Treatment Approaches for Lower-Risk MDS With RAS Mutations

July 20th 2023

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

July 20th 2023

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

Bexmarilimab Plus SOC Continues to Show Early Activity in R/R AML and MDS

July 19th 2023

Bexmarilimab in combination with standard-of-care azacitidine or azacitidine plus venetoclax demonstrated early signs of efficacy in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

July 19th 2023

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

What is the Role of Bispecifics in Relapsed/Refractory DLBCL?

July 17th 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy

July 17th 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Evolving Treatment Landscape of Relapsed/Refractory Follicular Lymphoma

July 14th 2023

A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.

Recent Treatment Guideline Updates in Follicular Lymphoma

July 14th 2023

Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.

Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management

July 13th 2023

Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.

Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

July 13th 2023

Panelists review the presented patient profile and shares how they would have approached treatment.

Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

July 13th 2023

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

July 12th 2023

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

LOTIS-9 Trial of Loncastuximab Tesirine/Rituximab in Untreated DLBCL Pauses Enrollment

July 11th 2023

ADC Therapeutics has voluntarily paused enrollment to the phase 2 LOTIS-9 trial investigating the combination of loncastuximab tesirine and rituximab for use in unfit or frail patients with previously untreated diffuse large B-cell lymphoma.

Intensified Frontline ABVD Improves PFS in Advanced Classical Hodgkin Lymphoma

July 10th 2023

Dose-dense and dose-intense doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) generated an improvement in progression-free survival and other efficacy end points compared with PET-adapted ABVD in previously untreated patients with advanced classical Hodgkin lymphoma.

Dr Erba on the Initial Safety and Activity of Ziftomenib in AML

July 10th 2023

Harry P Erba, MD, PhD, discusses the safety profile and preliminary activity of the investigational menin inhibitor ziftomenib in acute myeloid leukemia.

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.